Perioperative medicine & outcomes
Preoperative SGLT2 Inhibitor Use and Postoperative Diabetic Ketoacidosis
Authors' conclusion
This study found that preoperative use of SGLT2i medications in patients undergoing emergency surgery was not associated with an increased risk for postoperative diabetic ketoacidosis compared with no use of SGLT2i medications.
Study context
- Population
- Adults (≥18 years) with type 2 diabetes in commercial or Medicare fee-for-service plans undergoing 1 of 13 emergency surgeries, 2016–2022
- Participants
- 34,671 adults
- Exposure
- Preoperative SGLT2i use vs no SGLT2i use
- SGLT2in = 2,607
- No SGLT2in = 32,064reference
- Outcome
- Diabetic ketoacidosis, defined by diagnosis codes
- Follow-up
- 0 to 14 days after surgery
Methodological detailsnationwide claims sample, covariate-adjusted
- Nationwide claims sample
- Covariate-adjusted
Main finding
As reported in the abstract
Postoperative DKA, adjusted incidence
Observational data: associations, not effects.
Further findings
Postoperative DKA, unadjusted incidence · 0 to 14 days after surgery
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Preoperative SGLT2 Inhibitor Use and Postoperative Diabetic Ketoacidosis. JAMA Surg. Published 1 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →